Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Blog: No Easy Cure For Britain’s Brexit Madness

Executive Summary

Prime Minister Boris Johnson has until 19 October to agree a deal, or otherwise must ask for another Brexit extension. But he's in no mood to follow the rules.

You may also be interested in...



Many Firms Still Not Ready For No-Deal Brexit, Says UK BIA

The UK BioIndustry Association has warned that a wide range of life sciences companies, including small and medium sized firms, are still not fully aware of what a no-deal Brexit might mean for them.

UK Opposition Party Wants Compulsory Licenses For ‘Extortionate’ Medicines

The UK’s main opposition party says it would use compulsory licensing to ensure access to “extortionately” priced medicines. Unsurprisingly, the responses are polarized.

Compulsory License On Table In UK For Orkambi

The UK government will consider all options to improve access to Vertex’s cystic fibrosis treatment, including compulsory licensing.

Topics

Related Companies

UsernamePublicRestriction

Register

SC125921

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel